<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Biopharma News Feed - Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Tue, 11 Mar 2025 21:41:03 +0000</lastBuildDate><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item></channel></rss>